PRESCRIBING VIBERZI
On this page:
VIBERZI dosing 
Patient tips 

For the treatment of Irritable Bowel Syndrome with Diarrhea (IBS-D) in adults

WITH VIBERZI, START WITH A THERAPEUTIC DOSE—NO TITRATION NEEDED

K58.0=IBS-D
ICD code provided for informational purposes only. It represents no statement, promise or guarantee by Allergan concerning coverage and/or levels of reimbursement, payment or charge and is not intended to increase or maximize reimbursement by any payer. It is the responsibility of the healthcare provider to determine the appropriate code(s) for services provided to his or her patient. Please consult applicable payer organization with regard to local or actual coverage, reimbursement policies and determination processes.

VIBERZI is a non-narcotic, Schedule IV medication.1 Schedule IV is defined as having low potential for abuse and low risk for dependence2

HELP YOUR PATIENTS STAY ON TRACK

Here are some tips you can share with patients to help them stay on track with their
VIBERZI treatment:

Start a routine

Since VIBERZI is 1 tablet, taken twice a day with food, a good way for patients to remember their dose is to take 1 tablet in the morning with breakfast and 1 tablet in the evening with dinner.

Set the clock

Suggest that patients set a daily alarm or reminder on their phone reminding them when to take their medication.

Stay on top of refills

Encourage your patients to fill their VIBERZI prescription right away. You may also want to suggest that they sign up for refill reminders through their pharmacy.

Skip what was missed

Remind patients that if they miss a dose, they should skip the missed dose and take the next dose at their regular time. Patients should not take 2 doses at the same time.

Speak up early, completely, and often

Encourage patients to always be open with you about how they're feeling. The more they tell you, the better you will understand how to manage their symptoms.

Patient Savings Program

Savings card available!

The reality of living with IBS-D

Watch Ask Me Anything.

VIBERZI patient brochure

Information about VIBERZI and IBS-D.

VIBERZI samples

Download the form to request samples.

Not eligible where prohibited by law.

Next: Resources and Support  

Contraindications

VIBERZI is contraindicated in patients:

Warnings and Precautions
Pancreatitis:
Sphincter of Oddi Spasm:
Hypersensitivity Reactions:
Constipation:
Adverse Reactions

The most commonly reported adverse reactions (incidence >5% and greater than placebo) were constipation, nausea, and abdominal pain.

Indication

VIBERZI is indicated in adults for the treatment of irritable bowel syndrome with diarrhea (IBS-D).

Please also see full Prescribing Information.

 
IMPORTANT SAFETY INFORMATION
See More
Contraindications

VIBERZI is contraindicated in patients:

  • Without a gallbladder.
  • With known or suspected biliary duct obstruction, or sphincter of Oddi disease or dysfunction; a history of pancreatitis; or structural diseases of the pancreas.
  • With alcoholism, alcohol abuse, alcohol addiction, or who drink more than 3 alcoholic beverages per day.
  • With a known hypersensitivity reaction to VIBERZI.
  • With severe hepatic impairment.
  • With a history of chronic or severe constipation or sequelae from constipation, or known or suspected mechanical gastrointestinal obstruction.
Warnings and Precautions
Pancreatitis:
  • Pancreatitis, with or without sphincter of Oddi spasm, has been reported in patients taking either the 75 mg or 100 mg dosage of VIBERZI, including serious cases resulting in hospitalization, primarily in patients without a gallbladder. Fatal cases have also been reported in patients without a gallbladder. VIBERZI is contraindicated in patients without a gallbladder. Most of the reported cases of serious pancreatitis occurred within a week of starting treatment with VIBERZI and some patients developed symptoms after one to two doses.
  • In patients with a gallbladder, evaluate a patient’s alcohol intake prior to starting VIBERZI. Instruct patients to avoid chronic or acute excessive alcohol use while taking VIBERZI. Monitor for new or worsening abdominal pain that may radiate to the back or shoulder, with or without nausea and vomiting. Instruct patients to immediately stop VIBERZI and seek medical attention if they experience symptoms suggestive of pancreatitis such as acute abdominal or epigastric pain radiating to the back or shoulder associated with elevations of pancreatic enzymes with or without nausea and vomiting.
Sphincter of Oddi Spasm:
  • There is a risk of sphincter of Oddi spasm, resulting in pancreatitis or hepatic enzyme elevation associated with acute abdominal pain (eg, biliary-type pain) in patients taking VIBERZI. Serious adverse reactions of sphincter of Oddi spasm with or without pancreatitis resulting in hospitalization have been reported, primarily in patients without a gallbladder. Cases of serious sphincter of Oddi spasm occurred within a week of starting treatment with VIBERZI and some patients developed symptoms after one to two doses.
  • Instruct patients to immediately stop VIBERZI and seek medical attention if they experience symptoms suggestive of sphincter of Oddi spasm such as acute worsening of abdominal pain that may radiate to the back or shoulder with or without nausea and vomiting, associated with elevations of pancreatic enzymes or liver transaminases. Do not restart VIBERZI in patients who developed biliary duct obstruction while taking VIBERZI.
Hypersensitivity Reactions:
  • In postmarketing experience, serious hypersensitivity reactions (including anaphylaxis) have been reported following VIBERZI administration. Some of these reactions occurred after the first one or two doses of VIBERZI.
  • Instruct patients to immediately stop VIBERZI and seek medical attention if they experience symptoms suggestive of a hypersensitivity reaction.
Constipation:
  • Constipation, sometimes requiring hospitalization, has been reported following VIBERZI administration. In postmarketing experience, severe cases with development of intestinal obstruction, intestinal perforation, and fecal impaction, requiring intervention, have also been reported. Instruct patients to stop VIBERZI and immediately contact their healthcare provider if they experience severe constipation. Avoid use with other drugs that may cause constipation.
Adverse Reactions

The most commonly reported adverse reactions (incidence >5% and greater than placebo) were constipation, nausea, and abdominal pain.

Indication

VIBERZI is indicated in adults for the treatment of irritable bowel syndrome with diarrhea (IBS-D).

Please also see full Prescribing Information.